Interaction of human Thy-1 (CD 90) with the integrin αvβ3 (CD51/CD61): An important mechanism mediating melanoma cell adhesion to activated endothelium

Oncogene

Volumn 24, Issue 29, 2005, Pages 4710-4720

  Saalbach, Anja ^a   Wetzel, Anne ^b   Haustein, Uwe Frithjof ^a   Sticherling, Michael ^b   Simon, Jan C ^b   Anderegg, Ulf ^a  

^a Saxon Academy of Science in Leipzig   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

v 3; Adhesion; Endothelial cell; Melanoma; Thy 1

Indexed keywords

CD51 ANTIGEN; CD61 ANTIGEN; THY 1 ANTIGEN;

ARTICLE; CARCINOGENICITY; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; ENDOTHELIUM; FLOW; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR GROWTH;

ANTIGENS, THY-1; CELL ADHESION; ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; NEOPLASM METASTASIS; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 22744438812     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208559     Document Type: Article

References (44)

1. Ahrens T, Assmann V, Fieber C, Termeer C, Herrlich P, Hofmann M and Simon JC. (2001). J. Invest. Dermatol., 116, 93-101.
2. Anasagasti MJ, Olaso E and Calvo F. (1997). J. Natl. Cancer Inst., 89, 645-651.
3. Aubert C, Rouge F, Reillaudou M and Metge P. (1993). Int. J. Cancer, 54, 784-792.
4. Averbeck M, Braun T, Pfeifer G, Sleeman J, Dudda J, Martin SF, Kremer B, Aktories K, Simon JC and Termeer C. (2004). Eur. J. Immunol., 34 (10), 2708-2719.
5. Bean MA, Bloom BR, Heberman RB, Old LJ, Oettgen HF, Klein G and Terry WD. (1975). Cancer Res., 35, 2902-2913.
6. Buckley CD, Doyonnas R and Newton JP. (1996). J. Cell Sci., 109, 437-445.
7. Byzova T-V, Kim W, Midura R-J and Plow E-F. (2000). Exp. Cell Res., 254, 299-308.
8. Carey TE, Takahashi T, Resnick LA, Oettgen HF and Old LJ. (1976). Proc. Natl. Acad. Sci. USA., 73, 3278-3282.
9. Chambers A-F and Matrisian L-A. (1997). J. Natl. Cancer Inst., 89, 1260-1270.
10. Cheresh D-A and Spiro R-C. (1987). J. Biol. Chem., 262, 17703-17711.
11. Craig W, Kay R, Cutler R-L and Lansdorp P-M. (1993). J. Exp. Med., 177, 1331.
12. Crawford J-M and Barton R-W. (1986). Lab. Invest., 54, 122-135.
13. Duczmal A, Schollhammer S, Katich S, Ebeling O, Schwartz-Albiez R and Altevogt P. (1997). Biochem. Biophys. Res. Commun., 232, 236-239.
14. Ebeling O, Duczmal A and Aigner S. (1996). Eur. J. Immunol., 26, 2508-2516.
15. Felding-Habermann B and Cheresh D-A. (1993). Curr. Opin. Cell Biol., 5, 864-868.
16. Felding-Habermann B, Mueller B-M, Romerdahl C-A and Cheresh D-A. (1992). J. Clin. Invest., 89, 2018-2022.
17. Felding-Habermann B, Silletti S and Mei F. (1997). J. Cell. Biol., 139, 1567-1581.
18. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP. (1973). J. Natl. Cancer Inst., 51, 1417-1423.
19. Johnson J-P. (1999). Cancer Metastasis Rev., 18, 345-357.
20. Köhler G and Milstein C. (1975). Nature, 256, 495-497.
21. Kumar CC, Armstrong L, Yin Z, Malkowski M, Maxwell E, Ling H, Yaremko B, Liu M, Varner J, Smith EM, Neustadt B and Nechuta T. (2000). Adv. Exp. Med. Biol., 476, 169-180.
22. Leyton L, Schneider P and Labra CV. (2001). Curr. Biol., 11, 1028-1038.
23. Lockshin A, Giovanella BC, Vardeman DM, Mendoza JT, Quian C, Kozielski T and Stehlin Jr JS. (1985). J. Natl. Cancer Inst., 74, 899-903.
24. Meyer T and Hart I-R. (1998). Eur. J. Cancer, 34, 214-221.
25. Muller D, Breathnach R, Engelmann A, Millon R and Bronner G. (1991). Int. J. Cancer, 48, 550-556.
26. Murray G-I, Duncan M-E, O'Neil P, McKay J-A, Melvin W-T and Fothergrill J-E. (1996). Nat. Med., 2, 461-462.
27. Orosz P, Kruger A, Hubbe M, Ruschoff J, Von Hoegen P and Mannel D-N. (1995). Int. J. Cancer, 60, 867-871.
28. Orr F-W, Wang H-H, Lafrenie R-M, Scherbarth S and Nance D-M. (2000). J. Pathol., 190, 310-329.
29. Piali L, Hammel P, Uherek C, Bachmann F, Gisler R-H, Dunon D and Imhof B-A. (1995). J. Cell Biol., 130, 451-460.
30. Saalbach A, Anderegg U, Bruns M, Schnabel E, Herrmann K and Haustein U-F. (1996). J. Invest. Dermatol., 106, 1314-1319.
31. Saalbach A, Haustein U-F and Anderegg U. (2000). J. Invest. Dermatol., 115, 882.
32. Saalbach A, Hildebrandt G, Haustein U-F and Anderegg U. (2002). Microvasc. Res., 264, 86.
33. Saalbach A, Kraft R, Herrmann K, Haustein U-F and Anderegg U. (1998). Arch. Dermatol. Res., 290, 360-366.
34. Saalbach A, Wetzig T, Haustein U-F and Anderegg U. (1999). Cell. Tissue Res., 298, 307.
35. Smith J-W and Cheresh D-A. (1990). J. Biol. Chem., 265, 2168-2172.
36. Varner JA and Cheresh D-A. (1996). Adv. Oncol., 69-87.
37. Vidal M, Morris R, Grosveld F and Spanopoulou E. (1990). EMBO J., 9, 833-840.
38. Voura E-B, Ramjeesingh R-A, Montgomery A-M-P and Siu C-H. (2001). Mol. Biol. Cell, 12, 2699-2710.
39. Wandel E, Graßhoff A, Mittag M, Haustein U-F and Saalbach A. (2000). Exp. Dermatol., 9, 34-41.
40. Wandel E, Raschke A and Hildebrandt G. (2002). Arch. Dermatol. Res., 293, 601-608.
41. Weerasinghe D, McHugh K-P, Ross F-P, Brown E-J, Gisler R-H and Imhof B-A. (1998). J. Cell Biol., 142, 595-607.
42. Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, Anderegg U and Saalbach A. (2004). J. Immunol., 172, 3850-3859.
43. Williams AF. (1982). Biosci. Rep., 2, 277-287 (review).
44. Yoshizaki T, Sato H and Maruyama Y. (1997). Cancer, 79, 139-144.